ABSTRACT

Background: Polycystic ovary syndrome (PCOS) is the most common endocrine disease in women of reproductive age and is estimated to affect 5-10% of the population [1]. Prominent features of the syndrome include menstrual dysfunction, infertility, elevated androgen levels and insulin resistance [1, 2]. Women with PCOS have a clustering of cardiovascular risk factors, such as obesity, dyslipidemia, impaired glucose tolerance, and hypertension. Homocysteine has been recognized recently as a risk factor for cardiovascular diseases. Preliminary investigations suggest that high sensitivity C-reactive protein, homocysteine and adiponectin are abnormal in women with PCOS. The possible determinants of elevated homocysteine concentration are still debated among authors who found significant correlations between homocysteine and insulin resistance or hyperandrogenism.

Aim: The purpose of this study is to evaluate homocysteine levels in the PCOS population compared with controls.

INTRODUCTION

PCOS is the most common endocrine disease in women of reproductive age and is estimated to affect 5-10% of the population [1]. Prominent features of the syndrome include menstrual dysfunction, infertility, elevated androgen levels and insulin resistance [1, 2]. Women with PCOS have a clustering of cardiovascular risk factors, such as obesity, dyslipidemia, impaired glucose tolerance, and hypertension. Preliminary investigations suggest that serum biomarkers of cardiovascular disease such as high sensitivity C-reactive protein, homocysteine and adiponectin are abnormal in women with PCOS [3, 4]. Homocysteine is an amino acid formed by the conversion of methionine to cysteine. It is metabolized by trans-sulfuration and remethylation.

Recent data have shown an increased prevalence of cardiovascular disease [5] and higher cardiovascular morbidity in women with PCOS [6, 7]. Framingham Offspring Study has demonstrated, that hyperhomocysteinemia is associated with hyperinsulinemia and may partially account for increased risk of CVD associated with insulin resistance [8]. Insulin inhibits the hepatic cystathionine β synthetase activity, which increases serum homocysteine. Plasma homocysteine levels have been shown to correlate with blood pressure [9] and BMI [10]. Homocysteine is thought to impair implantation by interfering with the endometrial blood flow and its vascular integrity, which may contribute to early miscarriage [11, 12].

The possible determinants of elevated Homocysteine concentration are still debated among authors who found significant correlations between Homocysteine and insulin resistance or hyperandrogenism [13-15]. The purpose of this study is to evaluate homocysteine levels in the PCOS population compared with controls.

MATERIALS AND METHODS

The present study was carried out in department of biochemistry, Mamata Medical College and General Hospital, Khammam, India. The study was approved by Institutional human ethical committee. Informed consent was obtained from the patients selected. One hundred forty two subjects with PCOS were taken as the cases from the department of obstetrics and gynaecology unit of Mamata General Hospital, Khammam and Symalas hospitals, Khammam, Andhra Pradesh, India. Sixty five age and sex matched healthy individuals are taken as the controls [Table/Fig-1]. Controls included were volunteers from relatives of the patients, staff and students. The diagnosis was based on Rotterdam criteria [16]. Body weight, height and waist circumference were measured and BMI was calculated as weight (kg) divided by height in square meter (m²). Waist circumference is a measure of abdominal or centralized obesity, and is taken as midpoint between the lower margin of last palpable rib and top of iliac crest. Homocysteine was measured using Axix Homocysteine Enzyme Immunoassay (EIA). Five ml of blood was collected from the subjects as well as controls after overnight fasting (12 hours) by venipuncture.

PCOS cases were categorised into normal (BMI<23), overweight (BMI 23-25) and obese (BMI≥25). Patients were divided into two groups based on the BMI, subgroup 1 consisting of patients with normal BMI (<23) and subgroup 2 consisting of patients with increased BMI (≥23)(overweight+obese). Based on waist circumference, PCOS were categorized into two groups, normal cases (waist<80) and obese cases (waist≥80). Controls were also sub categorized based on BMI and waist.

Study design: Cross sectional comparative study

Inclusion Criteria: All the patients in the age group of 20-35 were...
diagnosed for PCOS using Rotterdam criteria. Subjects with normal kidney function were included.

Exclusion Criteria: The subjects having Diabetes mellitus, Hypertension, Coronary heart disease and endocrine disorders were excluded. Alcoholics, smokers, pregnant women, subjects on vitamin supplementation and subjects with altered kidney function (random urinary protein >16mg/dl, serum creatinine >1.1mg/dl) are also excluded from the study.

STATISTICAL ANALYSIS
All values were expressed as mean ± SD. The results obtained were analysed statistically using the unpaired student ‘t’ test to evaluate the significance of differences between the mean values.

RESULTS

Prevalence of obesity is more in PCOS cases compared to controls. When compared with BMI central obesity is more pronounced in PCOS cases [Table/Fig-1]. The mean BMI and waist circumference were increased in PCOS cases when compared to controls. Serum homocysteine is increased in PCOS cases when compared with controls [Table/Fig-2].

Based on BMI

<table>
<thead>
<tr>
<th>Cases (n=142)</th>
<th>Controls (n=65)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Normal cases (n=61): 43% (&lt;23)</td>
<td>Normal controls (n=32): 49% (&lt;23)</td>
</tr>
<tr>
<td>Overweight cases (n=26): 18% (23-25)</td>
<td>Overweight controls (n=20): 31% (23-25)</td>
</tr>
<tr>
<td>Obese cases (n=55): 39% (≥ 25)</td>
<td>Obese controls (n=13): 20% (≥ 25)</td>
</tr>
</tbody>
</table>

Based on waist

Normal cases (n=58): 41% (<80) | Normal controls (n=34): 52% (<80) |
Obese cases (n=84): 59% (≥ 80) | Obese controls (n=31): 48% (≥ 80)

**DISCUSSION**

Homocysteine has been recognized recently as a risk factor for cardiovascular diseases. Our data showed that serum homocysteine levels were significantly higher in PCOS women than controls. Our findings are consistent with a previous study by Loverro et al., [17] and Badawy et al., [18]. Mancini et al., [19] in their study found no significant difference in homocysteine levels among PCOS women and controls. Studies by Ilhan Tarkun et al., have shown correlation between homocysteine and BMI [20]. Schachter et al., [13], has shown correlation between homocysteine and insulin resistance. Mohan SK. and Priya V V have found that increased homocysteine levels and decreased antioxidant capacity may contribute to the increased risk of cardiovascular disease in women with PCOS [21]. Sagar Salehpour et al., have evaluated homocysteine levels in PCOS subjects based on BMI matched subjects. In our study homocysteine levels were compared among PCOS cases and controls as well as in subgroups based on BMI and waist circumference [22].

In our study mean serum homocysteine levels showed significant increase in PCOS cases. The increase was more pronounced with increase in BMI and waist. Higher levels were observed in obese cases when compared with normal cases and controls. The increasing global prevalence of obesity may play a key role in promoting the development of PCOS in susceptible individuals. In addition, there is no doubt that obesity aggravates preexisting clinical, hormonal and metabolic features in most women with PCOS [23].

Homocysteine has a well-known role in cardiovascular morbidity and mortality with its atherogenic and prothrombotic properties. Molecular mechanisms of homocysteine-induced cellular dysfunction include increased inflammatory cytokine expression, induction of oxidative stress, activation of apoptosis, defective methylation [24].

The metabolite of homocysteine can combine with LDL-cholesterol to produce foam cells and atherosclerotic plaques. Free radicals formed during the oxidation of reduced homocysteine may directly injure endothelial cells. Marked platelet aggregation may be secondary to the pro-aggregatory effects of homocysteine. Prolonged exposure of endothelial cells to homocysteine impairs production of nitric oxide. Hyperhomocysteinemia has been linked to myocardial infarction and recurrent coronary events.

**Based on Waist**

Based on waist cases were divided into two subgroups: Normal and obese; there was significant increase in the mean values [Table/Fig-5]. When comparison was made between subgroups based on waist: normal controls, normal cases, obese controls, and obese cases, significant increase of mean serum homocysteine level was observed in normal and obese cases compared with respective controls. Significant incremental increase of serum homocysteine was observed from normal controls, obese controls, normal cases and obese cases [Table/Fig-6].

**Based on Waist**

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Normal cases (Waist &lt; 80)</th>
<th>Obese cases (Waist ≥ 80)</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Waist</td>
<td>73.241±4.0533</td>
<td>88.167±5.9492</td>
<td>&lt;0.0001*</td>
</tr>
<tr>
<td>Homocysteine</td>
<td>8.919±2.1000</td>
<td>10.971±2.9311</td>
<td>&lt;0.0001*</td>
</tr>
</tbody>
</table>

**DISCUSSION**

Homocysteine has been recognized recently as a risk factor for cardiovascular diseases. Our data showed that serum homocysteine levels were significantly higher in PCOS women than controls. Our findings are consistent with a previous study by Loverro et al., [17] and Badawy et al., [18]. Mancini et al., [19] in their study found no significant difference in homocysteine levels among PCOS women and controls. Studies by Ilhan Tarkun et al., have shown correlation between homocysteine and BMI [20]. Schachter et al., [13], has shown correlation between homocysteine and insulin resistance. Mohan SK. and Priya V V have found that increased homocysteine levels and decreased antioxidant capacity may contribute to the increased risk of cardiovascular disease in women with PCOS [21]. Sagar Salehpour et al., have evaluated homocysteine levels in PCOS subjects based on BMI matched subjects. In our study homocysteine levels were compared among PCOS cases and controls as well as in subgroups based on BMI and waist circumference [22].

In our study mean serum homocysteine levels showed significant increase in PCOS cases. The increase was more pronounced with increase in BMI and waist. Higher levels were observed in obese cases when compared with normal cases and controls. The increasing global prevalence of obesity may play a key role in promoting the development of PCOS in susceptible individuals. In addition, there is no doubt that obesity aggravates preexisting clinical, hormonal and metabolic features in most women with PCOS [23].

Homocysteine has a well-known role in cardiovascular morbidity and mortality with its atherogenic and prothrombotic properties. Molecular mechanisms of homocysteine-induced cellular dysfunction include increased inflammatory cytokine expression, induction of oxidative stress, activation of apoptosis, defective methylation [24].

The metabolite of homocysteine can combine with LDL-cholesterol to produce foam cells and atherosclerotic plaques. Free radicals formed during the oxidation of reduced homocysteine may directly injure endothelial cells. Marked platelet aggregation may be secondary to the pro-aggregatory effects of homocysteine. Prolonged exposure of endothelial cells to homocysteine impairs production of nitric oxide. Hyperhomocysteinemia has been linked to myocardial infarction and recurrent coronary events.
Homocysteine promotes leukocyte recruitment by upregulating monocyte chemotractant protein-1 and interleukin-8 expression and secretion. Homocysteine increases smooth muscle cell proliferation and enhances collagen production. Prothrombotic effects of homocysteine include attenuation of endothelial cell tissue plasminogen activator binding sites, activation of factor VIIIa and V, inhibition of protein C and heparin sulfate, increased fibrinoprotein A and prothrombin fragments 1 and 2, increased blood viscosity, and decreased endothelial antithrombotic activity due to changes in thrombomodulin function [22].

CONCLUSION

Our study has demonstrated that mean serum homocysteine concentrations are increased in women with PCOS. The increase was more pronounced with increase in BMI and waist. Higher levels were observed in obese cases when compared with normal cases and controls. There is a growing body of evidence demonstrating disturbed Homocysteine metabolism in PCOS women. As PCOS is associated with various factors like insulin resistance, obesity, oxidative stress, dyslipidemia which are interlinked and aggravated by hyperhomocysteinemia may have more pronounced risk. Further studies are required to clarify the role of homocysteine in human reproductive physiology and to elucidate the mechanism to link these factors and aim at better treatment for PCOS to prevent short term as well as long term complications.

Screening for homocysteine status may be beneficial. Vitamin supplementation (folic acid, B6, B12) can improve pregnancy outcome and can reduce cardiovascular risk. The results of our study emphasize the need for initiating life style measures early and in the overweight category itself. This will supplement PCOS treatment and can help in management of PCOS.

REFERENCES


PARTICULARS OF CONTRIBUTORS:

1. Assistant Professor, Department of Biochemistry, Mamata Medical College, Khammam, Andhra Pradesh, India.
2. Professor, Department of Biochemistry, Mamata Medical College, Khammam, Andhra Pradesh, India.
3. Professor, Department of Biochemistry, Mamata Medical College, Khammam, Andhra Pradesh, India.
4. Assistant Professor, Department of Physiology, Mamata Medical College, Khammam, Andhra Pradesh, India.
5. Assistant Professor, Department of Biochemistry, Mamata Medical College, Khammam, Andhra Pradesh, India.

NAME, ADDRESS, E-MAIL ID OF THE CORRESPONDING AUTHOR:

Dr. Priyanka Maleedhu,
H No. 4-2-478, Police Housing Colony, Near Mamata Medical College, Rotary Nagar, Khammam – 507002, India.
Phone: 93932/46688, E-mail: priya.maleedhu@gmail.com

FINANCIAL OR OTHER COMPETING INTERESTS: None.